

Biocon Biologics Limited

CIN: U24119KA2016PLC093936

Biocon House, Tower-3,
Semicon Park Electronic City, Phase - II,
Hosur Road, Bengaluru, Karnataka 560100 IN**T** +91 080-6775 6775, **F** +91 080-6775 1030**E** contact@bioconbiologics.comwww.bioconbiologics.com

May 21, 2025

Singapore Exchange Securities Trading Limited

4 Shenton Way # 02-01

SGX Centre 2 Singapore 068807

Dear Sir/Madam,

Subject: Company Statement

Please find enclosed the company statement titled “**Biocon Biologics and Yoshindo Expand Access to Ustekinumab Biosimilar in Japan**”.

Kindly take the same on record and acknowledge.

Thanking you

Your faithfully

For Biocon Biologics Limited

Akhilesh Nand**Company Secretary**

Membership No. ACS 13669

Address: Biocon House, Semicon Park

Tower 3, Electronic City Phase 2, Hosur Road

Bengaluru, Karnataka

Encl: as above

NOTIFICATION TO STOCK EXCHANGE
COMPANY STATEMENT

**Biocon Biologics and Yoshindo Expand Access to
Ustekinumab Biosimilar in Japan**

Bengaluru, Karnataka, India, May 21, 2025

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that its commercial partner in Japan, Yoshindo Inc., has launched **Ustekinumab BS Subcutaneous Injection [YD]**, a biosimilar to the reference product Stelara® (ustekinumab). The biosimilar ustekinumab, developed and manufactured by Biocon Biologics, is commercialized and marketed in Japan by Yoshindo Inc.

Ustekinumab, a monoclonal antibody, is approved for the treatment of **psoriasis vulgaris** and **psoriatic arthritis (PsA)**.

In April 2024, the [Company entered into a settlement and licensing agreement](#) with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) to **commercialize Ustekinumab in Japan** upon regulatory approval. Biocon Biologics' biosimilar Ustekinumab BS Subcutaneous Injection [YD] [was approved by the Pharmaceuticals and Medical Devices Agency \(PMDA\)](#) of Japan in December 2024.

Biocon Biologics has already launched Ustekinumab in the [United States](#) and Europe in February 2025 to help patients manage their chronic conditions.

– Company Spokesperson